No Data
No Data
Express News | Pfizer Inc - Trial Meets Primary Endpoint With Sasanlimab Combination
Express News | Pfizer Inc - Results Shared With Global Health Authorities for Regulatory Filings
Express News | Pfizer Inc - Phase 3 Crest Trial Shows 32% Risk Reduction With Sasanlimab
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Express News | Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in Bcg-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer's Stock Outlook: Analysts Weigh In on Future Prospects